WORCESTER, Mass., Aug. 24, 2009 (GLOBE NEWSWIRE) -- Anna E. Gluskin, the chairman, president and CEO of Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), was featured this morning on "Market News" on Canada's Business News Network (BNN) to discuss the current circumstances of H1N1 and how Generex's synthetic vaccine platform can respond to the swine flu's ever-changing DNA. The segment can be viewed online at http://watch.bnn.ca/clip206593#clip206594 and will be available later today at www.generex.com.
Interviewed by program host Pat Bolland, Gluskin explained how the company's synthetic vaccines differ from traditional egg-based vaccines. While traditional egg-based vaccines take months to develop and rely on live virus -- which always carries the risk of infecting rather than inoculating -- Generex's synthetic vaccine platform does not use live virus. Instead, peptides are arranged to create a "snapshot" of the virus activate the body's T-cells to fight off the foreign invader, completely eliminating any risk of infection and resulting in potentially more effective vaccines that can be produced much more quickly and at approximately 1/10th the cost of egg-based vaccines. The more than 182,000 cases of swine flu already reported to WHO this year underline the importance of being able to quickly produce mass quantities of an effective vaccine as inexpensively as possible.
Generex's vaccine platform is already in various stage clinical trials for avian flu, as well as prostate, breast and ovarian cancers, melanomas, SARS and HIV/AIDS.
In addition to the company's vaccine platform technology, Generex has developed a range of products based on their proprietary RapidMist(tm) platform technology for drug delivery through the inner lining of the mouth, ensuring that there is no deposit in the lungs. The company's flagship product, Generex Oral-lyn(tm) is an oral insulin spray product for the treatment of Type-1 and Type-2 diabetes, available to patients in certain overseas markets and in Phase III global clinical trials.
Generex has also developed and markets Glucose RapidSpray(tm), an over-the-counter product designed for use early in the onset of a low blood sugar episode; BaBOOM!(tm) Energy Spray, a convenient and great-tasting energy spray alternative to energy drinks; and Crave-NX(tm) 7-Day Diet Aid Spray, clinically tested and designed to quickly curb cravings throughout the day. The company is also developing MetControl(tm), a chewing gum form of the common generic Metformin pill.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.